NIMH Radio: Dr. Andrew Pieper of the UT Southwestern Medical Center explains how his team discovered a memory enhancing compound in living mice.

Dr. Mark George of the Medical University of South Carolina talks about rTMS research and treatment resistant depression

A comprehensive behavioral therapy is more effective than basic supportive therapy and education in helping children with Tourette syndrome manage their tics, according to a study funded by the National Institute of Mental Health (NIMH). The study was published May 19, 2010, in a special issue of the Journal of the American Medication Association dedicated to mental health.

Dr. John Piacentini of UCLA talks about CBIT, a new therapy that treats tics associated with Tourette's Syndrome

Dr. Eric Nestler of the Mt. Sinai School of Medicine explains deltaFosB research and what it could mean for depression treatment

A study in rats has revealed striking gender difference in the brain’s stress response that could shed light on women’s proneness to mood and anxiety disorders. Female rat brain cells were more sensitive to a key stress hormone than males’, which could adapt to the hormone in a way female cells couldn’t.

Dr. Rita Valentino describes a discovery in rat brains that may explain why women are more prone than men to mood and anxiety disorders.

Best-selling author and journalist Judith Warner met with NIMH Director, Tom Insel . Warner has written extensively about American family culture, raising children in today's society, and now, the challenges faced by families of children diagnosed with mental disorders. Ms. Warner is a former contributing columnist for the New York Times and was a special correspondent for Newsweek in Paris.

BDNF stands for brain derived neurotrophic factor. This molecule, found in the brain's fear hub could have a significant impact on the study of anxiety disorders including Post Traumatic Stress Disorder. Dr. Francis Lee of Weill-Cornell Medical College is a leading BDNF investigator and was a recent guest lecturer at the National Institute of Mental Health.

Forest Laboratories, Inc. (NYSE: FRX) and Gedeon Richter Plc. today announced preliminary top-line results from an 8-week Phase II clinical trial of the novel, investigational antipsychotic agent cariprazine for the treatment of bipolar depression. Cariprazine is currently undergoing Phase III trials for separate indications of schizophrenia and bipolar mania...